Protein suppresses prostate cancer growth in lab tests
Updated: 2011-01-31 17:58:00
UK scientists have shown that a natural protein that occurs inside cells can suppress the growth of prostate cancer cells in the laboratory.
WASHINGTON -- The FDA failed to approve an indication for the benign prostatic hyperplasia (BPH) drug dutasteride (Avodart) for use in prostate cancer prevention.
Gary Schwitzer's HealthNewsReview Blog Gary Schwitzer Publisher , HealthNewsReview.org feedback healthnewsreview.org Mingle mammograms parties more incomplete info promoting screening By Gary Schwitzer on January 27, 2011 2:37 PM No Comments No TrackBacks Some weeks like this one just unfold recurring themes just roll your way whether you're looking for them or not . I was not looking for imbalanced screening test promotions when this week began , but I've certainly had a number cross my desk . I just learned of a St . Paul Pioneer Press story that promoted the fact that Regina Medical Center's Mingle Mammograms' parties offer food , drink and spa treatments to ease the fears and discomfort associated with the procedure , and to encourage women to get screened every year . It's hospital
AOL MAIL Complete our survey for a chance at 1,000 AOL Health Main Diseases Conditions ADHD Mens Sexual Health Allergies Obesity Alzheimer's Plastic Surgery Breast Cancer Skin Conditions Cancer Sleep Disorders Cold and Flu Smoking Cessation Diabetes Stroke Depression Stomach Pain Erectile Dysfunction Women's Sexual Health Heart Disease See All Conditions Family Health Caregiver Support Senior's Health Children's Health Teen Health Men's Health Women's Health Healthy Living Anti Aging Healthy Eating Beauty Skincare Memory Better Body Better Living Relationships Dental Health Sleep Health Happiness Stress Diet Fitness America Takes it Off Experts Celebrity Fitness Diet Success Motivation Experts Tools Symptom Checker Compare Medicare Plans Veggie Fruit Tracker Drug Interaction Checker Doctor
Cancer Research UK today (Thursday) launches a new Centre which will accelerate the pace of research in Glasgow and see the city become a world leader in the development of new treatments tailored for individual cancer patients.
Gary Schwitzer's HealthNewsReview Blog Gary Schwitzer Publisher , HealthNewsReview.org feedback healthnewsreview.org New England Science Writers blogging panel By Gary Schwitzer on January 18, 2011 2:21 PM No Comments No TrackBacks I'll be in Boston tomorrow as part of a panel discussion on blogging about health and science an event hosted by New England Science Writers , a professional organization of about 240 reporters , writers , freelancers , producers , bloggers , authors and . communicators I'll join this stellar group of bloggers on the : panel Daniel Carlat http : carlatpsychiatry.blogspot.com Ivan Oransky http : embargowatch.wordpress.com http : retractionwatch.wordpress.com Rachel Zimmerman http : commonhealth.wbur.org Moderated by Alison Bass http : alison-bass.blogspot.com
Eventhough screening for prostate cancer with the Prostate Specific Antigen (PSA) test in men ages 50-70 can detect the cancer before it becomes symptomatic, knowing whether screening is beneficial for these men is uncertain. Recent trials have shown small or no reductions in prostate cancer mortality among those screened. The small potential for benefit must be balanced against the more common and immediate downsides of increasing the chance of prostate cancer diagnosis and therapy-related complications........
Men who have a baseline PSA value of 10 or higher the first time they are tested are up to 11 times more likely to die from prostate cancer than are men with lower initial values, as per Duke University Medical Center researchers. Researchers say the finding, appearing early online in the journal Cancer, supports routine, early prostate-specific antigen (PSA) screening among healthy men with normal life expectancy a practice several studies have recently questioned........
Prostate cancer advances when tumors become resistant to hormone treatment, which is the standard therapy for patients, and begin producing their own androgens. Scientists at UT Southwestern Medical Center have observed that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth........
Some types of prostate tumors are more aggressive and more likely to metastasize than others. Nearly one-third of these aggressive tumors contain a small nest of particularly dangerous cells known as neuroendocrine-type cells. More rarely, some aggressive prostate tumors are made up entirely of neuroendocrine-type cells. The presence of neuroendocrine-type cancer cells is linked to a poor prognosis, but spotting these rare cells can be like finding a needle in a haystack. Now, as per a research findings reported in the July 13 issue of Cancer Cell, a team of researchers led by Ze'ev Ronai, Ph.D. at Sanford-Burnham Medical Research Institute (Sanford-Burnham) has identified a series of proteins that might make it easier for doctors to better diagnose the more metastatic forms of prostate cancer........
Patients with prostate cancer who receive brachytherapy and remain free of disease for five years or greater are unlikely to have a recurrence at 10 years, as per a research studyin the July 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO)........
Consumption of 50 g or more of alcohol per day or four or more drinks per day for at least five days per week was linked to an elevated risk for prostate cancer. Furthermore, drinking 50 g or more of alcohol per day rendered therapy with finasteride ineffective. Scientists analyzed data from 2,129 participants with cancer and 8,791 participants without disease from the Prostate Cancer Prevention Trial. They examined the relationships between risk for low- and high-grade prostate cancer and total alcohol consumption, types of alcoholic beverages and consumption pattern. Scientists also analyzed the effect of alcohol consumption on the effectiveness of finasteride based on the arms that patients were randomly assigned to in the original trial........
In what could lead to a major advance in the therapy of prostate cancer, researchers now know exactly why polyphenols in red wine and green tea inhibit cancer growth. This new discovery, published online in The FASEB Journal (http://www.fasebj.org), explains how antioxidants in red wine and green tea produce a combined effect to disrupt an important cell signaling pathway necessary for prostate cancer growth. This finding is important because it may lead to the development of drugs that could stop or slow cancer progression, or improve current therapys........
Johns Hopkins experts have found that men enrolled in an active surveillance program for prostate cancer that eventually needed surgery to remove their prostates fared just as well as men who opted to remove the gland immediately, except if a follow-up biopsy during surveillance showed high-grade cancer........
Van Andel Research Institute (VARI) researchers have determined how two proteins mandatory for the initiation and development of prostate cancer interact at the molecular level, which could lead to improved therapys for the disease. One of the proteins, androgen receptor, is already an important drug target for prostate cancer. The other, steroid receptor coactivator-3 (SRC3), was originally identified for its role in the development of breast cancer. SCR3 has also been characterized as a key factor in the development of prostate cancer, but, until now, the exact relationship between androgen receptor and SCR3 has been unclear........
Fewer prostate cancers were detected by prostate-specific antigen (PSA) screening in the U.S. than in a European randomized trial because of lower screening sensitivity, as per a new brief communication published online February 8 in the Journal of the National Cancer Institute To compare the PSA screening performance in a clinical trial with that in a population setting, Elisabeth M. Wever, MSc, Department of Public Health, Erasmus Medical Center, the Netherlands, and his colleagues applied a microsimulation model developed for prostate cancer and screening to the European Randomized Study of Screening for Prostate Cancer (ERSPC)Rotterdam. The model was adapted by replacing the trial's demography parameters with U.S.-specific ones and the screening protocol with the frequency of PSA tests in the population. The natural progression of prostate cancer and the sensitivity (percentage of men correctly identified as having prostate cancer of those who have preclinical prostate cancer) of a PSA test followed by a biopsy were assumed to be the same in the US as in the trial........
Prostate cancer cells are more likely to spread to other parts of the body if a specific gene quits functioning normally, as per new data from scientists at UT Southwestern Medical Center. Certain prostate cancer cells can be held in check by the DAB2IP gene. The gene's product, the DABIP protein, acts as scaffolding that prevents a number of other proteins involved in the progression of prostate cancer cells from over-activation. When those cells lose the DAB2IP protein, however, they break free and are able to metastasize, or spread, drastically increasing the risk of cancer progression in other organs as the cells travel through the bloodstream or lymph system........
A diagnosis of prostate cancer raises the question for patients and their physicians as to how the tumor will behave. Will it grow quickly and aggressively and require continuous therapy, or slowly, allowing treatment and its risks to be safely delayed? The answer may lie in the size and shape of the blood vessels that are visible within the cancer, as per research led by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in collaboration with the Harvard School of Public Health........
Scientists at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men appears to be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy........
Twenty years of screening for breast and prostate cancer - the most diagnosed cancer for women and men - have not brought the anticipated decline in deaths from these diseases, argue experts from the University of California, San Francisco and the University of Texas Health Science Center at San Antonio in an opinion piece reported in the "Journal of the American Medical Association"........
A small slice of RNA inhibits prostate cancer metastasis by suppressing a surface protein usually found on prostate cancer stem cells. A research team led by researchers at The University of Texas MD Anderson Cancer Center reported today in an advance online publication at Nature Medicine "Our findings are the first to profile a microRNA expression pattern in prostate cancer stem cells and also establish a strong rationale for developing the microRNA miR-34a as a new therapy option for prostate cancer," said senior author Dean Tang, Ph.D., professor in MD Anderson's Department of Molecular Carcinogenesis........
Scientists at Moores Cancer Center at the University of California, San Diego and his colleagues have observed that prostate cancer therapys varied significantly between county hospitals and private providers. Patients treated in county hospitals are more likely to undergo surgery while patients treated in private facilities tend to receive radiation or hormone treatment. These findings were published online by the journal Cancer on January 25........
Prostate cancer survivors can literally walk themselves to a lower risk of dying of the disease -- with some men achieving an almost 50% lower mortality risk, data from a large cohort study showed.